phosphorylcholine has been researched along with Angiospasm, Intracranial in 5 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine -Rho-kinase-activated Ca(2+)-sensitization in vitro and in subarachnoid hemorrhage (SAH) models in vivo and has also been shown to inhibit the occurrence of cerebral vasospasm (CIV) after the onset of SAH in a prospective, nonrandomized study." | 5.19 | A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study. ( Nakagawara, J; Ogasawara, K; Shirao, S; Suzuki, M; Tominaga, T; Yoneda, H, 2014) |
| "Inflammation has an important function in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH); however, the mediators of this inflammatory response have not been clearly identified." | 1.37 | Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries. ( Hunter, I; Mathieson, FA; Nixon, GF; Wirrig, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shirao, S | 3 |
| Yoneda, H | 3 |
| Shinoyama, M | 1 |
| Sugimoto, K | 1 |
| Koizumi, H | 1 |
| Ishihara, H | 1 |
| Oka, F | 1 |
| Sadahiro, H | 1 |
| Nomura, S | 1 |
| Fujii, M | 1 |
| Tamechika, M | 1 |
| Kagawa, Y | 1 |
| Owada, Y | 1 |
| Suzuki, M | 3 |
| Fujisawa, H | 1 |
| Kudo, A | 1 |
| Kurokawa, T | 1 |
| Kunitsugu, I | 1 |
| Ogasawara, K | 2 |
| Soma, M | 1 |
| Kobayashi, S | 1 |
| Ogawa, A | 1 |
| Wirrig, C | 1 |
| Hunter, I | 1 |
| Mathieson, FA | 1 |
| Nixon, GF | 1 |
| Nakagawara, J | 1 |
| Tominaga, T | 1 |
| Somlyo, AV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS): Effect of Eicosapentaenoic Acid on Cerebral Vasospasm Following Subarachnoid Hemorrhage[NCT00839449] | Phase 4 | 200 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Angiospasm, Intracranial
| Article | Year |
|---|---|
A prospective, multicenter, randomized study of the efficacy of eicosapentaenoic acid for cerebral vasospasm: the EVAS study.
Topics: Aged; Arachidonic Acid; Cardiovascular Agents; Combined Modality Therapy; Eicosapentaenoic Acid; Fem | 2014 |
4 other studies available for phosphorylcholine and Angiospasm, Intracranial
| Article | Year |
|---|---|
A novel trigger for cholesterol-dependent smooth muscle contraction mediated by the sphingosylphosphorylcholine-Rho-kinase pathway in the rat basilar artery: a mechanistic role for lipid rafts.
Topics: Amides; Animals; Antihypertensive Agents; Basilar Artery; beta-Cyclodextrins; Carotid Artery, Intern | 2015 |
Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway.
Topics: Animals; Basilar Artery; Benzopyrans; Cerebral Angiography; Cisterna Magna; Disease Models, Animal; | 2008 |
Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries.
Topics: Animals; Blood Platelets; Blotting, Western; Cells, Cultured; Cerebral Arteries; Chemokine CCL2; Ele | 2011 |
New roads leading to Ca2+ sensitization.
Topics: Animals; Calcium Signaling; Cattle; Cerebral Arteries; Heterotrimeric GTP-Binding Proteins; Humans; | 2002 |